- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about DK:NOVO/B
Recent news which mentions DK:NOVO/B
LifeMD’s stock soars 13% as company and Medifast to create weight-management program that includes GLP-1 drugs
December 13, 2023
From MarketWatch
Walmart seems to have changed its view of weight-loss drugs
December 06, 2023
From MarketWatch
Roche strikes $3.1 billion deal to buy obesity-drug maker Carmot Therapeutics billion in race to rival Novo Nordisk’s Ozempic
December 04, 2023
From MarketWatch
From MarketWatch
New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade
November 22, 2023
From MarketWatch
From MarketWatch
British Land leads U.K. real estate stocks higher amid optimism on rents
November 13, 2023
From MarketWatch
Weight-loss drug maker reports 56% profit surge, as it continues to limit supplies
November 02, 2023
From MarketWatch
From MarketWatch
From MarketWatch
The weight-loss drugs are coming for these companies — but here’s why Coke, others, may be spared, says JPMorgan
October 24, 2023
From MarketWatch
Here’s what Ozempic, ASML and India’s fintech industry all have in common — and how one ETF takes advantage of all three
October 17, 2023
From MarketWatch
What exactly are patients taking new weight-loss drugs eating and what are they avoiding? Bernstein asked them.
October 13, 2023
From MarketWatch
DaVita plays down Ozempic’s potential in treating kidney disease
October 12, 2023
From MarketWatch
From MarketWatch
From MarketWatch
Coca-Cola and PepsiCo’s stocks fall after Walmart says weight-loss drugs have customers cutting back on calories
October 06, 2023
From MarketWatch
This fund shows that industry expertise can help you make a lot of money in the stock market
October 02, 2023
From MarketWatch
Novo Nordisk, now Europe’s second-largest company by market cap, lifts outlook after 46% profit rise
August 10, 2023
Tickers
NVO
From MarketWatch
Viking Therapeutics stock gets boost from positive news that obesity drugs reduced risk of heart attacks and strokes
August 09, 2023
From MarketWatch
As obesity drugs help people eat less, these food companies could be the biggest losers
August 08, 2023
From MarketWatch
Eli Lilly’s stock soars toward best day in 23 years after strong earnings, upbeat Mounjaro outlook
August 08, 2023
From MarketWatch
Novo Nordisk’s Wegovy reduces risk of adverse cardiovascular events by 20% in obese adults
August 08, 2023
From MarketWatch
As Ozempic/Wegovy frenzy continues, Morgan Stanley lifts forecasts for weight-loss drugs to $77 billion
July 21, 2023
From MarketWatch
EU regulator is reviewing weight-loss drugs Ozempic and Wegovy for risk of suicidal thoughts and self-harm
July 11, 2023
From MarketWatch
From MarketWatch
From MarketWatch
Hit Wegovy weight-loss drug on track for $4 billion in U.S. sales despite supply constraints, analyst says
June 20, 2023
From MarketWatch
Inside the NASH drug boom: New drugs for a ‘silent’ liver disease that affects millions near FDA approval
February 13, 2023
From MarketWatch
From MarketWatch
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.